BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26325124)

  • 1. The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies.
    Ahmadzadeh V; Tofigh R; Farajnia S; Pouladi N
    Int Rev Immunol; 2016; 35(2):136-55. PubMed ID: 26325124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
    Safdari Y; Ahmadzadeh V; Farajnia S
    Invest New Drugs; 2016 Aug; 34(4):497-512. PubMed ID: 27075017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Tumor Microenvironment Regulates CD19 and CD20 Immunotherapy for Lymphoma.
    Lykken JM; Tedder TF
    Cancer J; 2015; 21(4):351-6. PubMed ID: 26222089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20-based therapy of B cell lymphoma: state of the art.
    Kosmas C; Stamatopoulos K; Stavroyianni N; Tsavaris N; Papadaki T
    Leukemia; 2002 Oct; 16(10):2004-15. PubMed ID: 12357351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
    Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
    J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
    Cheson BD; Leonard JP
    N Engl J Med; 2008 Aug; 359(6):613-26. PubMed ID: 18687642
    [No Abstract]   [Full Text] [Related]  

  • 8. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
    Grillo-López AJ; Kunkel L
    Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
    Shan D; Gopal AK; Press OW
    Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal anti-CD20 antibody therapy].
    Juhel L; Solal-Celigny P
    Rev Prat; 2004 Apr; 54(7):711-2. PubMed ID: 15253285
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-CD20 monoclonal antibodies: historical and future perspectives.
    Lim SH; Beers SA; French RR; Johnson PW; Glennie MJ; Cragg MS
    Haematologica; 2010 Jan; 95(1):135-43. PubMed ID: 19773256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
    Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
    Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma.
    Hernandez MC; Knox SJ
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1274-87. PubMed ID: 15275710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status and future impact of targeted therapies in non-Hodgkin lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Hematol; 2013 Apr; 6(2):191-202; quiz 203. PubMed ID: 23547867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell infiltrate after monoclonal anti-CD20 antibody therapy for B-cell lymphoma.
    Vincent-Salomon A; Mathiot C; Macintyre E; Girre V; Fourquet A; Mercier C; Fréneaux P; Dumont J; Decaudin D
    Leuk Lymphoma; 2000 Apr; 37(3-4):387-91. PubMed ID: 10752990
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies in the treatment of lymphoma.
    Leonard JP
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):210-1. PubMed ID: 16163182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.